Report Details

The global demand for the Adjuvant market was calculable at USD 760.3 Million in 2020 and is anticipated to come up with revenue of around USD 1,800.6 Million by finish of 2026, growing at a CAGR of around 11.1% between 2021 and 2026.

Global Adjuvant Market: Overview

An adjuvant is an element used in several vaccines that helps creates a powerful immune response in individuals getting the vaccine. Simply, adjuvant helps out vaccines work better. Many vaccines made from killed or damaged germs include natural adjuvant and help out the body generate a strong protective immune response. Moreover, adjuvant helps the body to produce an immune response strong enough to protect the person from the disease; a person is being vaccinated against. Adjuvanted vaccines can cause general reactions (such as swelling, redness, and pain at the injection site) and more systemic reactions (such as fever and body aches) than non-adjuvanted vaccines.

Adjuvant oncology care is a part of cancer treatments, that requires further cancer treatment after the achievement of the primary treatment and its main aim is to lessen the risk of cancer. Adjuvant therapy includes targeted therapy, chemotherapy, radiation therapy, biological therapy, and hormone therapy.

REPORT SNAPSHOT & REPORTING DATA TIMEFRAME
Parameter Details
Historical Date ( Actual Data) 2016 - 2020
Base Year Data 2020
Current Year Data 2021
Projected Data 2021 - 2026
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered product type, application, region
Regional scope North America; Europe; Asia Pacific; Central & South America; Middle East & Africa
Country Scope U.S.; Canada; Mexico; Germany; France; U.K.; China; Japan; South Korea; Singapore; Malaysia; Brazil; Saudi Arabia
Customization scope Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Adjuvant Market: Growth Factor

The increasing case of cancer at the global level is the major growth driving the global market of adjuvant oncology treatment. Along with this many positive initiatives taken by the governments and insurance companies for paying the treatment cost of cancers that has provided a major boost to the adjuvant market. Moreover, an increasing drive on research initiatives and efforts to discover more diseases that could be treated with adjuvant therapy is about to stimulate the adjuvant market growth in the forecast period.

Global Adjuvant Market: Segmentation

Based on the types of disease, the adjuvant market is segmented into sarcoma, breast cancer, Hodgkin’s lymphoma, colorectal cancer, glioblastoma, prostate cancer, lung cancer, and ovarian cancer. On the basis of applications, the adjuvant market is divided into immunotherapy, chemotherapy, radiotherapy, and others. In terms of revenue, breast cancer accounted for the significant growth of the market. Also, colorectal cancer will overtake all other segments in the forecast period.

Global Adjuvant Market: Regional Analysis

North America and Europe are dominating the market growth of adjuvant. This is due to the high incidences of cancer in the two continents. The greater means of people to spend on quality healthcare, positive reimbursements policies by the government, developed healthcare facilities are some major factors driving the markets. According to World Health Organization (WHO), 75% of countries across the globe have reported having an availability of cancer treatment services which consist of subsidized chemotherapy, cancer surgery, and cancer centers or department. In Europe, a remarkable 90% of countries reported having these cancer treatment services usually available.

Also, Asia Pacific is developing in terms of market share. The rising economies of India and China with their huge populations are key growth drivers. Increasing cases of cancer and developing healthcare infrastructure along with the increase in medical tourism in the region have boosted the adjuvant market growth so far.

Global Adjuvant Market: Competitive Players

Some major manufacturers in the adjuvant market cover BMS, Biogen, Sanofi, AstraZeneca PLC, Eli Lilly Co., Pfizer, Inc, and Amgen, Inc.

For example, in October 2020, Eli Lilly Co. declared that the National Institutes of Health (NIH) ACTIV-3 clinical trial estimating its monoclonal antibody, bamlanivimab (LYCoV555), found that bamlanivimab was not effective in treating people hospitalized with COVID-19. Moreover, in April 2021, the FDA revoked the use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when handled alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain infants.

Global Adjuvants Market: By Types

  • Sarcoma, Breast Cancer
  • Hodgkin’s Lymphoma
  • Colorectal Cancer
  • Glioblastoma
  • Prostate Cancer
  • Lung Cancer
  • Ovarian Cancer

Global Adjuvants Market: By Application

  • Immunotherapy
  • Chemotherapy
  • Radiotherapy
  • Others

Global Adjuvants Market: Regional Segmentation Analysis

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • The UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

 

Frequently Asked Questions

What are the key factors driving adjuvant market expansion?

The increasing case of cancer at global level is the major growth driving the global market of adjuvant oncology treatment. Along with this many positive initiatives taken by the governments and insurance companies for paying the treatment cost of cancers that has provided a major boost to the adjuvant market.

What will be the value of adjuvant market during 2021- 2026?

The global demand for the adjuvant market was estimated at approximately USD 760.3 Million in 2020 and is expected to generate revenue of around USD 1,800.6 Million by end of 2026, growing at a CAGR of around 11.1% between 2021 and 2026.

Which region will make notable contributions towards global adjuvant market revenue?

North America and Europe are dominating the market growth of adjuvant. This is due to the high incidences of cancer in the two continents.

What are the key players leveraging adjuvant market growth?

Some major manufacturers in the adjuvant market cover BMS, Biogen, Sanofi, AstraZeneca PLC, Eli Lilly Co., Pfizer, Inc, and Amgen, Inc. It studies the sales, revenues, market shares, and growth prospects of each of the players, besides throwing light on their key strategies.

 

Table Of Content

  • Chapter 1 Executive Summary
    • 1.1. Introduction of Adjuvant
    • 1.2. Global Adjuvant Market, 2020 & 2026 (USD Million)
    • 1.3. Global Adjuvant Market, 2016 – 2026(USD Million)
    • 1.4. Global Adjuvant MarketAbsulute Revenue Opportunity, 2016 – 2026(USD Million)
    • 1.5. Global Adjuvant MarketIncremental Revenue Opportunity, 2020 – 2026(USD Million)
  • Chapter 2 Adjuvant Market – Types Analysis
    • 2.1. Global Adjuvant Market – Types Overview
    • 2.2. Global Adjuvant Market Share, by Types, 2020 & 2026(USD Million)
    • 2.3. Sarcoma
      • 2.3.1. Global SarcomaAdjuvant Market, 2016 – 2026(USD Million)
    • 2.4. Breast Cancer
      • 2.4.1. Global Breast CancerAdjuvant Market, 2016 – 2026(USD Million)
    • 2.5. Hodgkin’s Lymphoma
      • 2.5.1. Global Hodgkin’s LymphomaAdjuvant Market, 2016 – 2026(USD Million)
    • 2.6. Culorectal Cancer
      • 2.6.1. Global Culorectal CancerAdjuvant Market, 2016 – 2026(USD Million)
    • 2.7. Glioblastoma
      • 2.7.1. Global GlioblastomaAdjuvant Market, 2016 – 2026(USD Million)
    • 2.8. Prostate Cancer
      • 2.8.1. Global Prostate CancerAdjuvant Market, 2016 – 2026(USD Million)
    • 2.9. Lung Cancer
      • 2.9.1. Global Lung CancerAdjuvant Market, 2016 – 2026(USD Million)
    • 2.10. Ovarian Cancer
      • 2.10.1. Global Ovarian CancerAdjuvant Market, 2016 – 2026(USD Million)
  • Chapter 3 Adjuvant Market – Appliaction Analysis
    • 3.1. Global Adjuvant Market – Appliaction Overview
    • 3.2. Global Adjuvant Market Share, by Appliaction, 2020 & 2026(USD Million)
    • 3.3. Immunotherapy
      • 3.3.1. Global ImmunotherapyAdjuvant Market, 2016 – 2026(USD Million)
    • 3.4. Chemotherapy
      • 3.4.1. Global ChemotherapyAdjuvant Market, 2016 – 2026(USD Million)
    • 3.5. Radiotherapy
      • 3.5.1. Global RadiotherapyAdjuvant Market, 2016 – 2026(USD Million)
    • 3.6. Others
      • 3.6.1. Global OthersAdjuvant Market, 2016 – 2026(USD Million)
  • Chapter 4 Adjuvant Market – Regional Analysis
    • 4.1. Global Adjuvant Market Regional Overview
    • 4.2. Global Adjuvant Market Share, by Region, 2020 & 2026(USD Million)
    • 4.3. North America
      • 4.3.1. North AmericaAdjuvant Market, 2016 – 2026(USD Million)
        • 4.3.1.1. North AmericaAdjuvant Market, by Country, 2016 - 2026(USD Million)
      • 4.3.2. North AmericaAdjuvant Market, by Types, 2016 – 2026
        • 4.3.2.1. North AmericaAdjuvant Market, by Types, 2016 – 2026(USD Million)
      • 4.3.3. North AmericaAdjuvant Market, by Appliaction, 2016 – 2026
        • 4.3.3.1. North AmericaAdjuvant Market, by Appliaction, 2016 – 2026(USD Million)
      • 4.3.4. U.S.
        • 4.3.4.1. U.S.Adjuvant Market, 2016 – 2026(USD Million)
      • 4.3.5. Canada
        • 4.3.5.1. CanadaAdjuvant Market, 2016 – 2026(USD Million)
    • 4.4. Europe
      • 4.4.1. EuropeAdjuvant Market, 2016 – 2026(USD Million)
        • 4.4.1.1. EuropeAdjuvant Market, by Country, 2016 - 2026(USD Million)
      • 4.4.2. EuropeAdjuvant Market, by Types, 2016 – 2026
        • 4.4.2.1. EuropeAdjuvant Market, by Types, 2016 – 2026(USD Million)
      • 4.4.3. EuropeAdjuvant Market, by Appliaction, 2016 – 2026
        • 4.4.3.1. EuropeAdjuvant Market, by Appliaction, 2016 – 2026(USD Million)
      • 4.4.4. Germany
        • 4.4.4.1. GermanyAdjuvant Market, 2016 – 2026(USD Million)
      • 4.4.5. France
        • 4.4.5.1. FranceAdjuvant Market, 2016 – 2026(USD Million)
      • 4.4.6. U.K.
        • 4.4.6.1. U.K.Adjuvant Market, 2016 – 2026(USD Million)
      • 4.4.7. Italy
        • 4.4.7.1. ItalyAdjuvant Market, 2016 – 2026(USD Million)
      • 4.4.8. Spain
        • 4.4.8.1. SpainAdjuvant Market, 2016 – 2026(USD Million)
      • 4.4.9. Rest of Europe
        • 4.4.9.1. Rest of EuropeAdjuvant Market, 2016 – 2026(USD Million)
    • 4.5. Asia Pacific
      • 4.5.1. Asia PacificAdjuvant Market, 2016 – 2026(USD Million)
        • 4.5.1.1. Asia PacificAdjuvant Market, by Country, 2016 - 2026(USD Million)
      • 4.5.2. Asia PacificAdjuvant Market, by Types, 2016 – 2026
        • 4.5.2.1. Asia PacificAdjuvant Market, by Types, 2016 – 2026(USD Million)
      • 4.5.3. Asia PacificAdjuvant Market, by Appliaction, 2016 – 2026
        • 4.5.3.1. Asia PacificAdjuvant Market, by Appliaction, 2016 – 2026(USD Million)
      • 4.5.4. China
        • 4.5.4.1. ChinaAdjuvant Market, 2016 – 2026(USD Million)
      • 4.5.5. Japan
        • 4.5.5.1. JapanAdjuvant Market, 2016 – 2026(USD Million)
      • 4.5.6. India
        • 4.5.6.1. IndiaAdjuvant Market, 2016 – 2026(USD Million)
      • 4.5.7. South Korea
        • 4.5.7.1. South KoreaAdjuvant Market, 2016 – 2026(USD Million)
      • 4.5.8. South-East Asia
        • 4.5.8.1. South-East AsiaAdjuvant Market, 2016 – 2026(USD Million)
      • 4.5.9. Rest of Asia Pacific
        • 4.5.9.1. Rest of Asia PacificAdjuvant Market, 2016 – 2026(USD Million)
    • 4.6. Latin America
      • 4.6.1. Latin AmericaAdjuvant Market, 2016 – 2026(USD Million)
        • 4.6.1.1. Latin AmericaAdjuvant Market, by Country, 2016 - 2026(USD Million)
      • 4.6.2. Latin AmericaAdjuvant Market, by Types, 2016 – 2026
        • 4.6.2.1. Latin AmericaAdjuvant Market, by Types, 2016 – 2026(USD Million)
      • 4.6.3. Latin AmericaAdjuvant Market, by Appliaction, 2016 – 2026
        • 4.6.3.1. Latin AmericaAdjuvant Market, by Appliaction, 2016 – 2026(USD Million)
      • 4.6.4. Brazil
        • 4.6.4.1. BrazilAdjuvant Market, 2016 – 2026(USD Million)
      • 4.6.5. Mexico
        • 4.6.5.1. MexicoAdjuvant Market, 2016 – 2026(USD Million)
      • 4.6.6. Rest of Latin America
        • 4.6.6.1. Rest of Latin AmericaAdjuvant Market, 2016 – 2026(USD Million)
    • 4.7. The Middle-East and Africa
      • 4.7.1. The Middle-East and AfricaAdjuvant Market, 2016 – 2026(USD Million)
        • 4.7.1.1. The Middle-East and AfricaAdjuvant Market, by Country, 2016 - 2026(USD Million)
      • 4.7.2. The Middle-East and AfricaAdjuvant Market, by Types, 2016 – 2026
        • 4.7.2.1. The Middle-East and AfricaAdjuvant Market, by Types, 2016 – 2026(USD Million)
      • 4.7.3. The Middle-East and AfricaAdjuvant Market, by Appliaction, 2016 – 2026
        • 4.7.3.1. The Middle-East and AfricaAdjuvant Market, by Appliaction, 2016 – 2026(USD Million)
      • 4.7.4. GCC Countries
        • 4.7.4.1. GCC CountriesAdjuvant Market, 2016 – 2026(USD Million)
      • 4.7.5. South Africa
        • 4.7.5.1. South AfricaAdjuvant Market, 2016 – 2026(USD Million)
      • 4.7.6. Rest of Middle-East Africa
        • 4.7.6.1. Rest of Middle-East AfricaAdjuvant Market, 2016 – 2026(USD Million)
  • Chapter 5 Adjuvant Market – Competitive Landscape
    • 5.1. Competitor Market Share – Revenue
    • 5.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    • 5.3. Strategic Developments
      • 5.3.1. Acquisitions and Mergers
      • 5.3.2. New Products
      • 5.3.3. Research & Development Activities
  • Chapter 6 Company Profiles
    • 6.1. Eli Lilly Co.
      • 6.1.1. Company Overview
      • 6.1.2. Product/ServicePortfulio
      • 6.1.3. Eli Lilly Co. Sales, Revenue, and Gross Margin
      • 6.1.4. Eli Lilly Co. Revenue and Growth Rate
      • 6.1.5. Eli Lilly Co. Market Share
      • 6.1.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 6.2. Amgen
      • 6.2.1. Company Overview
      • 6.2.2. Product/ServicePortfulio
      • 6.2.3. Amgen Sales, Revenue, and Gross Margin
      • 6.2.4. Amgen Revenue and Growth Rate
      • 6.2.5. Amgen Market Share
      • 6.2.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
      • 6.3. Inc.
      • 6.3.1. Company Overview
      • 6.3.2. Product/ServicePortfulio
        • 6.3.3. Inc. Sales, Revenue, and Gross Margin
        • 6.3.4. Inc. Revenue and Growth Rate
        • 6.3.5. Inc. Market Share
      • 6.3.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 6.4. BMS
      • 6.4.1. Company Overview
      • 6.4.2. Product/ServicePortfulio
      • 6.4.3. BMS Sales, Revenue, and Gross Margin
      • 6.4.4. BMS Revenue and Growth Rate
      • 6.4.5. BMS Market Share
      • 6.4.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 6.5. Biogen
      • 6.5.1. Company Overview
      • 6.5.2. Product/ServicePortfulio
      • 6.5.3. Biogen Sales, Revenue, and Gross Margin
      • 6.5.4. Biogen Revenue and Growth Rate
      • 6.5.5. Biogen Market Share
      • 6.5.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 6.6. Sanofi
      • 6.6.1. Company Overview
      • 6.6.2. Product/ServicePortfulio
      • 6.6.3. Sanofi Sales, Revenue, and Gross Margin
      • 6.6.4. Sanofi Revenue and Growth Rate
      • 6.6.5. Sanofi Market Share
      • 6.6.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 6.7. AstraZeneca PLC
      • 6.7.1. Company Overview
      • 6.7.2. Product/ServicePortfulio
      • 6.7.3. AstraZeneca PLC Sales, Revenue, and Gross Margin
      • 6.7.4. AstraZeneca PLC Revenue and Growth Rate
      • 6.7.5. AstraZeneca PLC Market Share
      • 6.7.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
    • 6.8. and Pfizer
      • 6.8.1. Company Overview
      • 6.8.2. Product/ServicePortfulio
      • 6.8.3. and Pfizer Sales, Revenue, and Gross Margin
      • 6.8.4. and Pfizer Revenue and Growth Rate
      • 6.8.5. and Pfizer Market Share
      • 6.8.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
      • 6.9. Inc.
      • 6.9.1. Company Overview
      • 6.9.2. Product/ServicePortfulio
        • 6.9.3. Inc. Sales, Revenue, and Gross Margin
        • 6.9.4. Inc. Revenue and Growth Rate
        • 6.9.5. Inc. Market Share
      • 6.9.6. Recent Initiatives, Funding/VC Activities, and Technulogical Innovations
  • Chapter 7 Adjuvant — Industry Analysis
    • 7.1. Introduction and Taxonomy
    • 7.2. Adjuvant Market – Key Trends
      • 7.2.1. Market Drivers
      • 7.2.2. Market Restraints
      • 7.2.3. Market Opportunities
    • 7.3. Value Chain Analysis
    • 7.4. Key Mandates and Regulations
    • 7.5. Technulogy Roadmap and Timeline
    • 7.6. Adjuvant Market – Attractiveness Analysis
      • 7.6.1. By Types
      • 7.6.2. By Appliaction
      • 7.6.3. By Region
  • Chapter 8 Industrial Chain, Sourcing Strategy, and Downstream Buyers
    • 8.1. Adjuvant Industrial Chain Analysis
    • 8.2. Downstream Buyers
    • 8.3. Distributors/Traders List
  • Chapter 9 Marketing Strategy Analysis
    • 9.1. Marketing Channel
    • 9.2. Direct Marketing
    • 9.3. Indirect Marketing
    • 9.4. Marketing Channel Development Trends
    • 9.5. Economic/Pulitical Environmental Change
  • Chapter 10 Report Conclusion& Key Insights
    • 10.1. Key Insights from Primary Interviews & Surveys Respondents
    • 10.2. Key Takeaways from Analysts, Consultants, and Industry Leaders
  • Chapter 11 Research Approach & Methodulogy
    • 11.1. Report Description
    • 11.2. Research Scope
    • 11.3. Research Methodulogy
      • 11.3.1. Secondary Research
      • 11.3.2. Primary Research
      • 11.3.3. Statistical Models
        • 11.3.3.1. Company Share Analysis Model
        • 11.3.3.2. Revenue Based Modeling
      • 11.3.4. Research Limitations

Inquiry For Buying

Adjuvant

Please fill out the form. We will contact you within 24 hours:
All fields required...

Request Sample

Adjuvant

Please fill out the form. We will contact you within 24 hours:
All fields required...
Inquiry For Buying

×

Avail Free PDF Sample Report

This website is secure and your personal details are safe. Privacy Policy

Thank you for contacting us.

Thank you for your interest in our research report.

We will be sending you the sample copy of the report shortly. Meanwhile, if you have any specific research requirement then please let us know. We will be glad to assist you in case you have any additional questions, so feel free to get in touch

Thank you


Warm regards,
Sales | Manager - International Business and partner Relations
Direct line: +1 347 535 0815
Market Research Store
E-mail: sales@MarketResearchStore.com | Web: www.MarketResearchStore.com